Form 8-K - Current report:
SEC Accession No. 0001193125-25-225853
Filing Date
2025-10-01
Accepted
2025-10-01 07:06:21
Documents
13
Period of Report
2025-09-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d940775d8k.htm   iXBRL 8-K 25720
2 EX-99.1 d940775dex991.htm EX-99.1 40464
  Complete submission text file 0001193125-25-225853.txt   187921

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA halo-20250930.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE halo-20250930_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE halo-20250930_pre.xml EX-101.PRE 10812
15 EXTRACTED XBRL INSTANCE DOCUMENT d940775d8k_htm.xml XML 3497
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 251362548
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)